FIELD: medicine; pharmaceuticals.
SUBSTANCE: group of inventions relates to a method of treating fibrosis, preferably pulmonary fibrosis, involving introduction of 4-[2-fluoro-4-[[[(2-phenylacetyl)amino]thioxomethyl]amino]-phenoxy]-7-methoxy-N-methyl-6-quinolinecarboxamide or salt thereof to a patient; as well as use of said compound or salt thereof for preparing a medicament for treating fibrosis.
EFFECT: group of inventions provides new agents for treating fibrosis.
8 cl, 1 ex, 2 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| AGENT FOR PULMONARY FIBROSIS CONTAINING PYRAZOLE DERIVATIVE | 2021 |
|
RU2817989C1 |
| USE OF GLYCYRRHETINIC ACID, GLYCYRRHIZIC ACID AND RELATED COMPOUNDS FOR PREVENTING AND/OR TREATING PULMONARY FIBROSIS | 2010 |
|
RU2575825C2 |
| MATERIALS AND METHODS OF TREATING CHRONIC FIBROUS DISEASES | 2006 |
|
RU2446825C2 |
| ORVEPITANT FOR CHRONIC COUGH TREATMENT | 2016 |
|
RU2746601C2 |
| PYRIMIDINE COMPOUND AND METHOD FOR ITS PRODUCTION | 2020 |
|
RU2790017C1 |
| THERAPEUTIC AGENT APPLICABLE IN PULMONARY FIBROSIS | 2009 |
|
RU2547571C2 |
| THERAPEUTIC AGENT FOR PULMONARY FIBROSIS | 2015 |
|
RU2678968C2 |
| ANTICANCER DRUG FOR THYROID CANCER | 2007 |
|
RU2448708C2 |
| HALOALLYLAMINE SULFONE DERIVATIVE AS LYSILOXIDASE INHIBITORS AND THEIR USE | 2019 |
|
RU2801092C2 |
| CYSTEAMINE DIOXYGENASE-RESISTANT ANALOGUES OF CYSTEAMINE AND THEIR USE | 2016 |
|
RU2766579C2 |
